Ann: Incannex to Acquire APIRx Pharmaceuticals, page-22

This is a game changer Ann. The IHL strategy has been to be the global IP leader in the sector - and this where the value is.

What a derisk to the business and I can only imagine the newsflow to come out of this!

BTW, here is the key IMO. If you look at the GW Pharma sale to Jazz for $7.2 Billion USD, most of their assets were IP related. This is where the real value is built. I think our OSA program is a Company Maker but now the probabilities for a suite of successful IP has gone up dramatically. We just jumped into the league of the multi billion dollar players. What a fantastic strategic move.